Optimization of radiotherapy fractionation schedules based on radiobiological functions by Pizarro, F. & Hernández, A.
BJR
Objective: To present a method for optimizing radio-
therapy fractionation schedules using radiobiological 
tools and taking into account the patient´s dose-volume 
histograms (DVH).
Methods: This method uses a figure of merit based on 
the uncomplicated tumour control probability (P+) and 
the generalized equivalent uniform dose (gEUD). A set 
of doses per fraction is selected in order to find the 
dose per fraction and the total dose, thus maximizing 
the figure of merit and leading to a biologically effective 
dose that is similar to the prescribed schedule.
Results: As a clinical example, a fractionation schedule 
for a prostate treatment plan is optimized and 
presented herein. From a prescription schedule of 
70 Gy/35 × 2  Gy, the resulting optimal schema, using 
a figure of merit which only takes into account P+, is 
54.4 Gy/16 × 3.4  Gy. If the gEUD is included in that 
figure of merit, the result is 65 Gy/26 × 2.5  Gy. Alter-
native schedules, which include tumour control prob-
ability (TCP) and the normal tissue complication 
probability (NTCP) values are likewise shown. This 
allows us to compare different schedules instead of 
solely finding the optimal value, as other possible clin-
ical factors must be taken into account to make the 
best decision for treatment.
Conclusion: The treatment schedule can be optimized 
for each patient through radiobiological analysis. The 
optimization process shown below offers physicians 
alternative schedules that meet the objectives of the 
prescribed radiotherapy.
Advances in knowledge: This article provides a simple, 
radiobiological-function-based method to take advan-
tage of a patient’s dose-volume histograms in order to 
better select the most suitable treatment schedule.
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intROduCtiOn
Radiobiological tools have been used in radiotherapy (RT) 
clinical decisions since the last century; however, most of 
the time, they have been used solely for managing treat-
ment interruptions.
Some efforts have been made to extend the use of said radio-
biological tools, such as the inclusion of biological evalua-
tion tools in some treatment planning systems.1 Likewise, 
there exist other computer applications that can be used to 
evaluate treatment plans.2–6 Some authors have proposed 
spatiotemporal optimization.7,8 It could be challenging to 
use these methods in RT departments with high workloads.
On the other hand, in many cases, new technologies in RT 
are able to easily meet objectives and handle constraints in 
terms of the planning target volume (PTV) and the organ at 
risk (OAR), respectively. This gives rise to the idea that other 
fractionation schedules are possible in addition to those used 
for classic conformal RT. If an OAR in two different treatment 
plans with the same fractionation schedule is irradiated much 
more in one plan than the other, then it would make sense to 
think that these two plans should not have the same schedule. 
Each plan would have its optimal fraction size. Nowadays, 
there exists a gap between the evolution of technology and 
the delivery of fractionation schedules.
The aim of this study is to present a simple method that uses 
radiobiological tools to optimize fractionation schedules, 
which complement the dosimetric improvements brought 
about by new treatment techniques. The method is based 
on patients’ dose-volume  histograms, thus giving rise to 
individualized optimization.
MethOdS And MAteRiAlS
The method is based on maximizing the uncompli-
cated tumour control probability (P+) function, where 
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Figure 1. Steps of optimization process. Optimal dose per fraction (d) and optimal total dose (Dtot) are the final result of the pro-
cess. Biologically effective dose (BED), dose-volume histogram (DVH), tumour control probability (TCP), normal tissue complica-
tion probability (NTCP) and uncomplicated tumour control probability (P+) are involved in different steps of this process.
dose for a fixed fraction size. The approach is based on studying 
P+ when the fraction size varies. In this way, a set of solutions for 
P+ is obtained, and their maximum will yield the optimal frac-
tionation schedule, that is to say, the optimal total dose for the 
optimal fraction size.
The schedule prescribed by the oncologist for the tumour is trans-
lated into biologically effective dose (BED).10 This BED is named 
BEDobj. A DVH for the PTV and another for the OAR are obtained 
from the treatment planning systems at this prescribed schedule. 
The criterion for choosing the OAR is that its final outcome must 
be as important as the loss of tumour control.
A summary of the process is shown in Figure 1. A set of doses per 
fraction must be selected (di, where i = 1 to n) to be used as soft-
ware input. The programme can manage up to n = 16 doses per 
fraction every time the application is run. The interval between 
doses is 0.1  Gy.
For every fraction size (di), total dose (Di) is determined so 
that the corresponding BED is equal  to BEDobj. For each Di, 
a new DVHtumour,i and a new DVHOAR,i will be obtained from 
the DVHtumour dose prescription and from DVHOAR, respec-
tively. For example, a DVH obtained for a total dose of 70 Gy 
can be translated into a DVH with a total dose of 72  Gy if 
every bin of the 70  Gy DVH is multiplied by the ratio 72/70. 
DVH only depends on the total dose.
The TCP, NTCP and P+ curves can be calculated from each of 
the newly calculated DVHs. There will be as many curves as 
fraction sizes, which make up the set n. The total dose value 
(Dtot,i - Figure 1) is a value whose P+ value is at its maximum for 
each fraction size, di. In general, Dtot,i will be different from Di. 
Lastly, the maximum value for the set’s P+ will correspond to the 
optimum fractionation.
As stated above, prescribed histograms are transformed to adapt 
each bin of the DVH for the total dose, which is changing. After 
that, the DVHs are transformed into their isoeffective doses in 
2 Gy fractions, using the linear-quadratic (LQ) formalism to 
take into account the changes in the doses per fraction. Also, 
within the process, a Monte Carlo method is used to describe 
inter-patient variability in sensitivity through α and β, the radio-
biological parameters of the LQ model. Specific α and β values 
are derived using pseudo-random numbers and the Weibull 
cumulative probability. The method requires knowing the mean 
α and β values, and their respective deviations, but these values 
are difficult to obtain, even in vitro, and caution must be used in 
the selection of said values. The process takes on the radiobio-
logical parameter uncertainties which are used to calculate TCP 
and NTCP indices.
Ebert conducted a study in which TCP and equivalent uniform 
dose (EUD) were analysed, concluding that EUD could 
be a more robust index for optimizing a treatment plan in 
which radiobiological parameters are not well known.11 He 
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Figure 2. Optimization example using the dose-volumen histograms (DVH) of a planning target volume (PTV) and an organ at 
risk (OAR) which correspond to a prostate and rectum, respectively. The option of gEUD's participation is set to NO. The opti-
mal schedule and total dose, whose BED = BEDobj for the optimal dose per fraction, are shown at the bottom right of the fig-
ure. gEUD, generalized equivalent uniform dose.
recommended that EUD and TCP indices are  to  be consid-
ered together as a more complete tool for evaluating dose. In 
order to follow this recommendation, a figure of merit, based 
on gEUD, was introduced.12,13 This figure of merit was defined 
as follows:











where gEUD0 represents the value which corresponds to the 
prescribed dose for the tumour and the dose for 50% complica-
tion probability (TD50) for the OAR.14
The total figure of merit that combines the notions of gEUD and 
P+ (whose value must be the maximum value) is calculated as:
 ftotal = P+i × fi (4)
where i ∈ (1, n).
Specialized in-house software, LQlab, has been developed 
to perform these calculations—while likewise having the 
ability to perform other radiobiological calculations of 
interest.15
ReSultS
To serve as a clinical example, a fractionation schedule for a pros-
tate treatment plan was optimized. This kind of tumour was chosen 
because of its low α/β ratio and the positive effect of hypofraction-
ated schedules. The rectum was selected because of its peculiarity of 
being the most critical OAR meeting the restrictions. The prescrip-
tion schedule was 70 Gy/35 × 2 Gy. Figure 2 shows the LQlab opti-
mization interface. The radiobiological parameters of the tumour 
(prostate) and the OAR’s complication (necrosis/stenosis) can be 
selected from a dropdown. The values included in the programme 
were taken from references.16,17 In any event, the application 
allows the user to change these parameters. The prescription dose, 
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the gEUD’s participation in  optimization and the initial fraction 
dose (d1) had to be specified as well.
The output is shown in table format. All the tested fraction dose 
values (Dses) are shown in the first column. For each of these 
fraction sizes, the optimization results are shown in rows as total 
dose (Dtot), sessions, TCP(%) and NTCP(%). LQlab highlights 
the optimal result from all those available. This optimal schedule 
is 54.4 Gy/16 × 3.4  Gy.  Figure 3 shows the maximum value for 
this set’s P+ at 3.4 Gy per fraction. Incidentally, the BED value is 
equal to BEDobj:
 BEDobj = BED (70 Gy/35 × 2 Gy)
= BED (54.4 Gy/16 × 3.4Gy)
 
The TCP and NTCP values for this optimal schedule are 89 and 
5.1%, respectively (Figure 2). These values are very close to the 
87.7 and 4.5% values obtained from the prescription schedule. 
In this case, the difference arises in terms of total treatment time 
-  the patient would finish treatment 27 days earlier with the 
optimal schedule.
In order to make use of the gEUD’s contribution, the “Partici-
pation of the gEUD in the optimization process” option must 
be set to YES.
In this case, the resulting optimal schedule is 65 Gy/26 × 2.5 Gy, 
and once again:
 BEDobj = BED (70 Gy/35 × 2 Gy)
= BED (65 Gy/26 × 2.5 Gy)
 
This last option, when selected, chooses schedules with lower 
fraction sizes, since the gEUD function does not negatively affect 
treatment time prolongation.
diSCuSSiOn
The absolute values of the TCP and NTCP depend on the uncer-
tainty of the radiobiological parameter values used in the TCP 
and NTCP models. Nevertheless, these optimization process 
results are independent from those absolute values, as the rele-
vance of these calculations stems from the relative differences 
among the values obtained from the different fraction sizes. 
What matters is for users to be able to compare different sched-
ules—not just select the optimal one. After all, dose response is 
accepted as being a complex issue that involves several factors, 
with RT being just one of those factors. The resulting optimal 
schedule may not be the best from a clinical point of view. This is 
the reason why it can be of interest to offer the physician several 
alternative schedules which would align with the prescription. 
Having alternatives of this type at one’s disposal is what could 
be most clinically applicable. Although P+ could lead low total 
doses, the user can always compare the biological effect of the 
prescription dose for the tumour to the calculated optimal 
schedule at the bottom right of Figure  2. In cases where BED 
< BEDobj, the users can add sessions to the optimal schedule or 
choose another schedule with a TCP which is equal to, or greater 
than, the medical prescription.
As a result, the trend in the future could be to prescribe in BED units 
instead of prescribing based on the total dose/dose per fraction 
pair, as said doses could be obtained after an optimization process. 
The dose prescription would, thus, be specific to each patient, as the 
patients’ DVHs have to be used in the process. That is to say, opti-
mization brings about an individualized dose prescription.
The clinical history of the patient and other concomitant or 
adjuvant treatments will have to be taken into account in 
order for optimal schedules with high doses per fraction to 
be acceptable. Likewise, a trustworthy immobilization system 
combined with image guidance would be necessary to deliver 
these high fraction sizes with an acceptable uncertainty level.
The results from different trials comparing radiation toxicity in 
hypo-fractionation versus conventional RT should likewise be 
taken into account.18 More specifically, in the case of the prostate 
cancer, some recent reviews highlight the precautions to be consid-
ered in the case of moderate hypo-fractionation (2.4–3.4  Gy); 
Figure 3. Calculated P+ values obtained through the TCP and NTCP values of the Figure 2 versus doses per fraction. The maximum 
value is located at 3.4  Gy per fraction whose optimal schedule is 54.4 Gy/16 × 3.4  Gy. NTCP, normal tissue complication proba-
bility; TCP, tumour control probability.
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extreme hypo-fractionation regimes (>4  Gy) should be restricted 
to prospective clinical trials.19
COnCluSiOnS
RT treatment schedules can be optimized on a patient-by-
patient basis through radiobiological analysis. The opti-
mization process discussed herein can provide physicians 
with alternative schedules which meet the objectives and 
constraints of the RT prescription. The patient history and the 
available technical resources for delivering treatments 
must be taken into account in order to accept the results 
yielded from the process in the event that the fraction dose 
increases.
